(NASDAQ: GH) Guardant Health's forecast annual revenue growth rate of 19.1% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.85%.
Guardant Health's revenue in 2025 is $773,996,000.On average, 9 Wall Street analysts forecast GH's revenue for 2025 to be $109,862,679,426, with the lowest GH revenue forecast at $109,132,978,841, and the highest GH revenue forecast at $110,193,460,506. On average, 9 Wall Street analysts forecast GH's revenue for 2026 to be $133,753,869,464, with the lowest GH revenue forecast at $128,224,126,575, and the highest GH revenue forecast at $141,324,048,453.
In 2027, GH is forecast to generate $165,367,496,899 in revenue, with the lowest revenue forecast at $157,461,705,195 and the highest revenue forecast at $189,899,312,017.